The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: A randomised double-blind placebo-controlled trial

Marie Fisk1‡*, Joseph Cheriyan1,2‡, Divya Mohan3,4, Julia Forman2, Kaisa M. Mäki-Petäjä1, Carmel M. McEniery1, Jonathan Fuld5, James H. F. Rudd6, Nicholas S. Hopkinson3, David A. Lomas7, John R. Cockcroft8, Ruth Tal-Singer4, Michael I. Polkey2, Ian B. Wilkinson1

1 Department of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, United Kingdom, 2 Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom, 3 NIHR Respiratory Biomedical Research Unit, Royal Brompton & Harefield NHS Foundation Trust and Imperial College, London, United Kingdom, 4 GSK R&D, King of Prussia, Pennsylvania, United States of America, 5 Department of Respiratory Medicine, University of Cambridge & Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom, 6 Department of Cardiovascular Medicine, University of Cambridge & Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom, 7 Department of UCL Respiratory, Division of Medicine, Rayne Building, University College London, London, United Kingdom, 8 Department of Cardiology, Wales Heart Research Institute, Cardiff University, Cardiff, United Kingdom

‡ These authors are joint first authors on this work.
* mf503@medschl.cam.ac.uk

Abstract

Background
Cardiovascular disease is a major cause of morbidity and mortality in COPD patients. Systemic inflammation associated with COPD, is often hypothesised as a causal factor. p38 mitogen-activated protein kinases play a key role in the inflammatory pathogenesis of COPD and atherosclerosis.

Objectives
This study sought to evaluate the effects of losmapimod, a p38 mitogen-activated protein kinase (MAPK) inhibitor, on vascular inflammation and endothelial function in chronic obstructive pulmonary disease (COPD) patients with systemic inflammation (defined by plasma fibrinogen >2.8g/l).

Methods
This was a randomised, double-blind, placebo-controlled, Phase II trial that recruited COPD patients with plasma fibrinogen >2.8g/l. Participants were randomly assigned by an online program to losmapimod 7.5mg or placebo tablets twice daily for 16 weeks. Pre- and post-
6118) (as a component study of the ERICA (Evaluation of the Role of Inflammation in Chronic Airways Disease) Collaboration, which includes academic partners and GSK. GSK made contributions towards study management and provision of study drug. JC, CMM and IBW acknowledge funding support from the NIHR Cambridge Comprehensive Biomedical Research Centre. This work was supported by the NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London who part fund MIP’s salary. The views expressed in this publication are those of the authors and not necessarily those of the NHS, The National Institute for Health Research or the Department of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** JRF, KMP, CMM, JHRF and NSH have no disclosures to declare. MF and IBW received an imaging award from GSK during the course of the study. JC is employed by Cambridge University Hospitals NHS Foundation Trust and is obligated to spend 50% of his time on GSK clinical trial research via a secondment agreement, representing a significant relationship; however, he receives no benefits or compensation from GSK. JF reports personal fees from GSK, outside the submitted work; MIP reports personal fees from GSK during the conduct of the study. JRC reports grants from GSK outside this submitted work, DM and RT-S are employees and shareholders of GSK. DAL reports grants from GlaxoSmithKline, personal fees from GSK and non-financial support from GSK, during the conduct of the study; and personal fees from GSK, grants from GSK, personal fees from Griffols, outside the submitted work.

**Introduction**

Chronic Obstructive Pulmonary Disease (COPD) is a complex condition, which is associated with extra-pulmonary manifestations, such as systemic inflammation and cardiovascular disease, that increase patient morbidity and mortality [1]. Current pharmacological treatments for COPD are generally limited to inhaled bronchodilators and corticosteroids, which do not address extra-pulmonary features. Diversifying therapeutic options to focus on systemic manifestations, and by implication more accurate stratification of COPD patients for such treatments, might improve clinical outcomes.

p38 mitogen-activated protein kinases (MAPK) are signalling molecules that regulate cellular responses to extra-cellular stresses [2]. They also regulate pro-inflammatory cytokines, and have a key role in the initiation and development of inflammatory diseases, including COPD and atherosclerosis [2] [3]. Therefore, pharmacological inhibition of the p38 MAPK pathway, may represent a potential novel approach to treating the adverse cardiovascular manifestations of COPD. To date, losmapimod (GW856553 Brentford UK), a selective p38α/β MAPK inhibitor has been evaluated as an anti-inflammatory therapy in different patient populations including COPD and cardiovascular disease. In COPD, losmapimod reduces acute phase circulating proteins such as fibrinogen, and a reduction in hyperinflation have been described [4]. In cardiovascular disease, losmapimod attenuated arterial inflammation in atherosclerosis [5], improved endothelial function in hypercholesterolemic subjects [6], and showed a trend towards improved left ventricular function following non-ST elevation myocardial infarction [7].

Arterial inflammation, measured by positron emission tomography (PET) imaging, is a promising vascular biomarker, which has been shown to improve prediction of cardiovascular events beyond traditional risk factors, and also informed on the timing of such events [8]. Brachial artery flow-mediated dilatation (FMD) is a measure of endothelial function which is associated with cardiovascular outcomes, and has prognostic value in different clinical cohorts [9]. COPD patients have increased arterial inflammation compared to healthy controls, regardless...
of smoking history [10], and also demonstrate impaired endothelial function [11]. Additionally, systemic inflammation is hypothesised to be a causal factor in the increased cardiovascular risk observed in COPD patients [1]. Plasma fibrinogen, a stable biomarker of systemic inflammation in COPD, is positively associated with cardiovascular risk in the general population, and is implicated in the development of vascular dysfunction and atherosclerosis [12]. It has also recently been qualified by the Food and Drug Administration (FDA) as a drug development tool for predicting the risk for COPD exacerbations, and mortality in COPD [13].

The EVOLUTION (Evaluation of Losmapimod in Chronic Obstructive Pulmonary Disease patients with systemic inflammation stratified by fibrinogen) trial, was an experimental medicine study, designed to test the hypothesis that losmapimod, as an anti-inflammatory agent, reduces arterial inflammation and concomitantly improves endothelial function (our co-primary endpoints of the study) in a cohort of COPD patients with evidence of systemic inflammation, stratified by plasma fibrinogen. Secondary endpoints included safety and tolerability of losmapimod, and the effects of losmapimod on arterial stiffness and blood biomarkers of inflammation.

**Materials and methods**

The EVOLUTION study design and protocol have been previously published [14] and the protocol (S1 Protocol) is included in the Supporting Information. Key trial information is summarised below.

**Study design**

EVOLUTION was a randomised, double-blind placebo-controlled, parallel-group, stratified experimental medicine trial, which recruited from two UK tertiary centres (Addenbrooke’s Hospital, Cambridge and the Royal Brompton Hospital, London). The study was approved by Cambridge South Research Ethics Committee and was registered with ClinicalTrials.gov (NCT01541852). It was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice standards, and written informed consent was obtained from all patients. The study was active from 1st April 2012 when the first patient was recruited till the 6th August 2014 when the final patient recruited completed the study. Based on sample size calculation, the planned recruitment target of the trial was met.

**Participants**

Eligible patients were aged 50–85 years, with a known diagnosis of COPD (confirmed by post-bronchodilator spirometry Forced Expiratory Lung Volume in 1 second/Forced Vital Capacity, (FEV$_1$/FVC ratio <0-70)), or with spirometry which fulfilled GOLD-Unclassified (GOLD-U: FEV$_1$/FVC $\geq$0.7 and FEV$_1$ <80% predicted) categorisation [15]. However, no GOLD-U patients were recruited to the study. All patients were current or ex-smokers with at least a 10-year pack year history and a plasma fibrinogen $>2.8g/L$. This level of plasma fibrinogen was selected as the stratification threshold for entry to the study because although there is no evidence of a fibrinogen threshold that stratifies for cardiovascular risk [16], values greater than 2.7g/L are associated with an increased risk of hospitalisation, and worse FEV$_1$ [17], (and poor lung function defined by FEV$_1$, is similarly associated with increased cardiovascular risk [18]). All patients maintained on their standard-of-care medications prior to and during the study, including prescribed medications for cardiovascular comorbidity and COPD. Full inclusion and exclusion criteria of the trial including information regarding amendment to the trial inclusion criteria, are reported in S1 and S2 Tables respectively, and a study flow-chart of visits and assessments performed are shown in S1 Fig. The trial consort diagram is shown in
Fig 1 with further information also provided in S3 Table. The consort checklist for the EVO-LUTION trial is found in S1 Appendix.

**Randomisation and masking**

Subjects were randomised (1:1) to receive either losmapimod 7.5mg or matching placebo twice daily for 16 weeks. An online coded program was used to randomise patients stratified by trial site. All trial personnel, including investigators giving trial interventions, assessing outcomes, and analysis of data, and patients were blinded throughout the study to treatment allocation. Study medication was provided by GSK.

**Assessments for primary endpoint**

**Vascular PET/CT imaging.** \(^{18}\)F-Fluorodeoxyglucose PET paired with attenuated corrected computed tomography (FDG PET/CT) imaging of the aorta and carotid arteries was performed before, and at 16 weeks of treatment, to evaluate tracer uptake as a surrogate measure of arterial inflammation. Further detailed information regarding imaging is explained in S1 Methods. For image analysis, Osirix open-source DICOM software v5.6 (Geneva, Switzerland) was used. A region of interest (ROI) including arterial wall and lumen was drawn on each axial slice of artery on the co-registered PET/CT scan and the maximum Standardised Uptake Value (SUVmax) recorded. Subsequently, each ROI was normalised by blood FDG concentration in the superior vena cava or jugular vein (for carotids), to yield an arterial maximum tissue-to-blood ratio (TBR) as a quantitative measure of arterial tracer uptake (Fig 2). Slices with a TBR >1.6, deemed ‘active slices’ were included in analyses.

The arteries were analysed as six arterial territories: the ascending, descending, abdominal aorta and right and left carotid arteries, and the aortic arch. For each arterial territory and each scan, the average TBR was calculated by taking the mean of the TBR across all of the slices in the territory with a TBR >1.6. This produced the TBR of each arterial territory, for each scan. Change in TBR was pre-defined as the change in average TBR, from post- to pre-dose scans.

The “index vessel” (defined as the arterial territory with the highest average TBR at baseline) was selected as the a priori focus of interest to determine change over time with treatment or placebo. Arterial territories that could be the index vessel included the ascending, descending, abdominal aorta or either carotid artery, but not the aortic arch because higher inter-observer variability in analysing this region was previously reported. [19] Additionally, we report the change in TBR in each arterial region individually, including the aortic arch. All scans were analysed by an experienced reader, anonymised to patient identifiable information, treatment group, and visit number.

**Endothelial function.** Endothelial function was assessed by brachial artery FMD pre- and post-treatment using established ultrasonography techniques [20]. FMD was defined as the maximum percentage increase in artery diameter, after release of a blood pressure cuff inflated to supra-systolic pressure for 5 minutes to induce ischemia distal to the site of measurement (reactive hyperemia). After a 10-minute break, endothelial-independent dilatation was then assessed. This is the maximum percentage increase in artery diameter after administration of 25 μg of sublingual glyceryl trinitrate (GTN).

**Assessments for secondary endpoints**

**Arterial stiffness.** Assessments were performed pre- and post-treatment. After a 15-minute rest, seated brachial blood pressure was recorded (OMRON-750CP, Omron Corp, Japan). Radial artery waveforms were then obtained using a high-fidelity micromanometer (SPC-301, Millar Instruments, Texas, USA) and recorded using SphygmoCor software (AtCor Medical,
Figure 1. Consort diagram of EVOLUTION trial. (*expanded in S3 Table).
Sydney, Australia), which generated a corresponding central waveform and aortic augmentation index using the software’s validated transfer function. Augmentation index is a composite measure of arterial wave reflections. Supine carotid-femoral aortic pulse wave velocity (aPWV), which is a measure of aortic stiffness, was also measured using the same device, as previously described [21].

**Systemic inflammation.** Blood samples were collected at days 0, 14, 28, 56, 84 and 112 (16 weeks) of treatment and 2-weeks following cessation of treatment, for measurement of plasma fibrinogen (Klauss method) [22], and high-sensitivity C reactive protein (hsCRP) using a clinically validated laboratory assay.

Fig 2. Calculation of arterial tissue-to-blood ratio (TBR) as a measure of arterial inflammation. Calculation of TBR: ratio of FDG tracer concentration in the artery divided by FDG concentration in the venous blood pool (superior vena cava for aorta, internal jugular for carotid).

https://doi.org/10.1371/journal.pone.0194197.g002
Safety. Adverse events, safety laboratory parameters and haemodynamic variables were assessed throughout the study and electrocardiograms (ECGs) were performed pre- and at 16 weeks of treatment.

Statistical analysis

This was an exploratory trial utilising a sample size calculation similar to our prior PET imaging trial of losmapimod in atherosclerotic patients on stable statin therapy [5]. We estimated that 30 COPD patients per treatment arm would provide a 90% chance of detecting a difference of 15% change from baseline TBR when comparing losmapimod to placebo. To estimate the treatment effect with 95% confidence intervals (CI) of losmapimod compared to placebo, change from baseline TBR (or percentage change from baseline FMD, for our co-primary endpoint of endothelial function) was analysed using linear regression models, with the change from baseline as the dependent variable, treatment as the independent variable, and baseline value and treatment site as covariates. Individual regression models were used for the primary endpoints of index vessel TBR, each arterial territory TBR, and FMD (and GTN), and since change from baseline value was the dependent variable, only patients with both baseline and follow up data were included in analysis. For FMD and GTN analyses, pre-test mean brachial artery diameter was also included as a covariate in each regression model. Similarly, secondary endpoints were examined using the same regression analysis technique to assess treatment effect of losmapimod versus placebo. Statistical analysis was performed per protocol, and excluded patients who required systemic corticosteroids within four weeks of post-dose assessments. The reason for excluding these patients from primary endpoint analysis was concern that recent treatment with systemic corticosteroids would confound analysis of the treatment effects of losmapimod. Safety analysis included all randomised patients who had received at least one dose of study drug (losmapimod or placebo). Blood biomarker data were log transformed prior to analysis. Post hoc analysis was performed that excluded subjects who had a COPD exacerbation at any time during the trial, where an exacerbation was defined as clinical deterioration in respiratory symptoms requiring treatment with antibiotics and/or systemic steroids. A post hoc analysis, which excluded patients with any known cardiovascular medical history at baseline (for example hypercholesterolemia, and therefore any patients on statins, or other cardiovascular medications), was performed. A p-value <0.05 was deemed significant for all statistical analyses. All data are presented as mean±standard deviation (SD), percentages, or with 95% confidence intervals (CI). Analyses were performed using R version 3.0.0 for Microsoft Windows with R-Studio version 0.98.953. Raw data of the trial are provided in S2 Appendix.

Results

The flow of participants in the trial is shown in the consort diagram (Fig 1) and further information is provided in the Supporting Information supplement (S3 Table). 160 participants were assessed for eligibility at enrolment, of whom 73 were randomised to receive either losmapimod (n = 36) or placebo (n = 37). Demographics and baseline characteristics of patients are summarised in Table 1. The mean age of the whole trial cohort was 68±7 years, 70% were male, 14% were current smokers, total pack years smoked were 47±25 years, FEV₁ was 1.35±0.58 litres (50±21% predicted). Mean fibrinogen pre-dose was 3.52±0.63 g/L and hsCRP was 5.64±7.39 mg/L.

Primary endpoints

Losmapimod did not significantly reduce the primary imaging endpoint of change in TBR in the index vessel compared to placebo, (treatment effect of losmapimod on TBR: -0.05,
Table 1. Demographics of the trial cohort by treatment group as baseline.

| Demographics                          | Losmapimod n = 36 | Placebo n = 37 |
|---------------------------------------|-------------------|----------------|
| Age (years)                           | 67±8              | 68±7           |
| Male                                  | 25 (69%)          | 26 (70%)       |
| Ex-smoker                             | 32 (88%)          | 34 (91%)       |
| Total pack years (n)                  | 48±24             | 43±25          |
| BMI (kg/m²)                           | 26±4              | 26±4           |

Cardiovascular medical history

| CVD disease*                          | 5 (14%)           | 3 (8%)         |
| Hypertension                          | 11 (31%)          | 7 (19%)        |
| Hypercholesterolaemia                 | 3 (8%)            | 4 (11%)        |

Spirometry

| FEV₁ (L)                              | 1.32±0.60         | 1.40±0.54      |
| FEV₁ percentage predicted (%)         | 50±19             | 52±22          |
| FVC                                   | 2.93±0.90         | 3.12±0.80      |
| FVC percentage predicted (%)          | 86±16             | 88±20          |

Concomitant inhaled respiratory medication †

| ICS and LABA (%)                      | 27 (75%)          | 29 (80%)       |
| ICS                                   | 2 (6%)            | 2 (6%)         |
| LABA                                  | 2 (6%)            | 4 (11%)        |
| LAMA                                  | 23 (63%)          | 27 (71%)       |

Haemodynamic assessment

| Systolic blood pressure (mmHg)        | 133±15            | 138±20         |
| Diastolic blood pressure (mmHg)       | 77±10             | 80±10          |
| Heart rate (bpm)                      | 74±12             | 74±12          |
| Augmentation Index (%)                | 28±9              | 25±10          |
| Aortic pulse wave velocity (%)        | 9.47±3.13         | 10.54±2.48     |

Systemic Inflammation

| hsCRP (mg/l)                          | 3.6 (2.1–4.9)     | 2.3 (1.2–7.5)  |
| Fibrinogen (g/l)                      | 3.5 (3.1–3.9)     | 3.3 (3.1–3.7)  |
| White cell count (x10⁹/L)             | 7.1 (5.7–8.3)     | 7.0 (5.7–8.1)  |

Concomitant cardiovascular medication

| Statins (%)                           | 12 (33%)          | 7 (19%)        |
| Beta-blockers (%)                     | 4 (11%)           | 0 (0%)         |
| Calcium-channel blockers (%)          | 8 (22%)           | 6 (16%)        |
| ACE inhibitors/A2RB (%)               | 9 (25%)           | 7 (19%)        |
| Anti-platelets (%)                    | 8 (22%)           | 4 (11%)        |

Mean±SD, median (IQR), n (%) are presented.

*CVD: history of angina, myocardial infarction, acute coronary syndrome, stroke, or revascularisation procedure. FEV₁: Forced Expiratory Lung Volume in 1 second.
FVC: Forced vital capacity. hsCRP: High sensitivity C-reactive protein.
†ICS and LABA: Combined inhaled corticosteroid and long acting beta agonist, ICS: inhaled corticosteroid, LABA: Long acting beta agonist, LAMA: Long acting muscarinic antagonist. ACE: Angiotensin, A2RB: Angiotensin 2 receptor blockers.

https://doi.org/10.1371/journal.pone.0194197.t001

(95% CI: -0.17, 0.07), p = 0.42; Fig 3). Table 2 summarises the average TBR of each anatomical arterial region pre- and post-dose, with point estimates of the treatment effect of losmapimod adjusted for placebo and site. S4 Table shows treatment effect data with coefficients of covariates from regression analyses also included. The aortic arch was the only anatomical region where there was a significant treatment effect of losmapimod on TBR compared to placebo.
Fig 3. Tissue-to-blood ratio (TBR) at baseline and 16 weeks treatment with losmapimod or placebo in the index vessel. Losmapimod had no significant treatment effect, overall significance p = 0.42. Lined bars = baseline, solid bars at 16 weeks. Bars = mean values, error bars = 95% CI.

https://doi.org/10.1371/journal.pone.0194197.g003

| Vessel       | Losmapimod | Placebo | Treatment Effect of Losmapimod | p-value of treatment effect |
|--------------|------------|---------|--------------------------------|----------------------------|
|              | Baseline   | 16 weeks| Baseline | 16 weeks | Point Estimate (95% CI) |                                |
|              | Mean±SD TBR| Mean±SD TBR |               |          |                          |                                |
| Index        | 2.12±0.29  | 1.96±0.29 | 1.99±0.21 | 1.93±0.23 | -0.05 (-0.17, 0.07)     | 0.42                           |
| Arch         | 2.10±0.28  | 1.95±0.23 | 1.92±0.20 | 1.93±0.19 | -0.12 (-0.22, -0.03)   | 0.01                           |
| Ascending    | 1.96±0.26  | 1.90±0.26 | 1.85±0.18 | 1.86±0.20 | -0.04 (-0.15, 0.06)    | 0.43                           |
| Descending   | 2.01±0.31  | 1.95±0.24 | 1.92±0.19 | 1.93±0.20 | -0.04 (-0.14, 0.07)    | 0.49                           |
| Abdominal    | 1.99±0.22  | 1.92±0.24 | 1.88±0.20 | 1.90±0.20 | -0.06 (-0.16, 0.03)    | 0.20                           |
| R Carotid    | 1.86±0.15  | 1.81±0.15 | 1.80±0.19 | 1.81±0.19 | -0.05 (-0.13, 0.04)    | 0.29                           |
| L Carotid    | 1.86±0.20  | 1.80±0.19 | 1.80±0.16 | 1.88±0.27 | -0.07 (-0.19, 0.07)    | 0.33                           |

R Carotid = right carotid, L Carotid = left carotid. Mean±SD are presented. Baseline TBR and treatment site are covariates in linear regression models used to calculate the treatment effect of losmapimod versus placebo, on each artery listed.

https://doi.org/10.1371/journal.pone.0194197.t002
For the co-primary endpoint of FMD, there was no significant treatment effect of losmapimod over placebo. The treatment effect of losmapimod did not change FMD significantly (+0.4%; 95% CI: -1.66, 2.47, p = 0.70). However, the effect of GTN was marginally higher (+3.25%; 95% CI: 0.41, 6.1, p = 0.03) in the losmapimod group compared to placebo, (Table 3 and Fig 4). Of note, there were no significant differences in either primary endpoint when stratified for study site. S4 Table shows treatment effect data with coefficients of covariates from regression analyses also included.

**Secondary endpoints**

For the secondary endpoint of arterial stiffness, there were no statistically significant differences in augmentation index or aPWV following treatment in the losmapimod or placebo groups. The treatment effects of losmapimod were also non-significant for augmentation index (+0.83%; 95% CI: -4.6%, p = 0.73), and aPWV (-0.01m/s; 95% CI: -0.95, 0.93 m/s, p = 0.98).

We observed a significant decrease in mean fibrinogen in the losmapimod group (10% reduction compared to 0.3% in placebo group) on Day 14 of treatment (treatment effect -0.08; 95% CI: -0.15, -0.01, p = 0.03 corrected for baseline and placebo). However, there were no differences in fibrinogen levels from 4 weeks of treatment onwards, although there was a trend

**Table 3. Percentage change in brachial artery diameter with flow-mediated dilatation (FMD), and dilatation after glyceryl trinitrate (GTN) administration in the losmapimod and placebo groups of the study.**

|                | Losmapimod | Placebo | Treatment effect of Losmapimod | p-value of treatment effect |
|----------------|------------|---------|--------------------------------|-----------------------------|
|                | Baseline   | 16 weeks | Baseline | 16 weeks | Point Estimate (95% CI) |                      |
| FMD %          | 4.80±2.56  | 5.80±3.48 | 4.17±2.75 | 5.06±4.04 | 0.40 | (-1.66, 2.47) | 0.70 |
| GTN %          | 11.12±4.60 | 14.46±7.04 | 9.05±3.28 | 9.77±4.76 | 3.25 | (0.41, 6.1) | 0.03 |

Mean±SD are presented. Linear regression models with covariates of baseline percentage change, treatment sites and pre-test mean brachial artery diameter, were used to calculate treatment effect of losmapimod on FMD and GTN.

https://doi.org/10.1371/journal.pone.0194197.t003

![Fig 4. A) Percentage change in brachial artery diameter due to flow-mediated dilatation (FMD). B) Percentage change in brachial artery diameter following GTN administration, at baseline and 16 weeks treatment with losmapimod or placebo. Losmapimod had no significant effect on FMD compared to placebo, p = 0.70, although there was significant change (p = 0.03) following GTN administration. Lined bars = baseline, solid bars at 16 weeks. Bars = mean values, error bars = 95% CI.](https://doi.org/10.1371/journal.pone.0194197.g004)
throughout the treatment period of the study, of greater attenuation in inflammatory biomarkers in the losmapimod group. A rebound of fibrinogen (albeit not hsCRP) above baseline, was observed two weeks after stopping losmapimod treatment. Fig 5 summarises the trajectory of fibrinogen and hsCRP values throughout the study.

Losmapimod was well tolerated in this COPD cohort. The frequency of adverse events reported was similar in the losmapimod and placebo groups (19 versus 12 due to COPD exacerbations, respectively, see S5 Table in the Supporting Information supplement). There were no clinically meaningful or statistically significant changes in laboratory parameters, vital signs, or ECGs over the course of the study in either treatment group. Serious adverse events (SAEs) were more frequent in the losmapimod treatment arm, and COPD exacerbations and pneumonia were the most common SAE reported (S4 Table).

Post hoc analysis

Due to the high number of COPD exacerbations reported in this biomarker-enriched trial, a pre-specified post hoc analysis was performed to examine only stable patients (excluding patients who had a COPD exacerbation anytime during the trial). This showed a significant treatment effect of losmapimod compared to placebo on index vessel TBR (-0.13; 95% CI: -0.25, -0.02, p = 0.02). However, there was still no significant treatment effect on FMD (-0.22%; 95% CI: -2.36, 1.92, p = 0.83). Furthermore, post hoc analysis excluding patients with known cardiovascular history (and on cardiovascular medication), showed no significant treatment effect of losmapimod versus placebo, on index vessel TBR (+0.10; 95% CI: -0.15, 0.13, p = 0.91), or FMD (+0.55%; 95% CI: -2.71, 3.81, p = 0.73).

Discussion

The primary finding of this experimental medicine study was that the anti-inflammatory p38 MAPK inhibitor, losmapimod, did not attenuate arterial inflammation nor improve endothelial function in systemically inflamed COPD patients, defined by a baseline fibrinogen >2.8 g/l. To our knowledge, this is the first time fibrinogen has been used as a stratification biomarker for entry into a drug trial, and arterial inflammation used as a primary endpoint in an interventional COPD clinical trial.

Although our primary endpoint was negative, overall there was a trend for greater reduction in arterial inflammation with losmapimod treatment compared to placebo in all vessel territories, although this only reached significance in the aortic arch, and a larger study size may have highlighted treatment differences compared to placebo more clearly. Interestingly, in post hoc analysis of stable COPD patients who did not exacerbate during the trial, a significant treatment effect of losmapimod on the index vessel was observed. The respective 7% and 16% reduction in TBR observed in the aortic arch in the whole cohort, and index vessel in post hoc analysis when COPD exacerbators were excluded, may have clinical implications. For example intervention studies report a 6–15% reduction in TBR with other anti-inflammatory treatments such as anti-tumour necrosis-α therapy in rheumatoid arthritis patients, or high-dose statins in atherosclerosis [23] [24].

This COPD cohort had higher levels of systemic inflammation and index vessel TBR, than we previously reported in stable atherosclerotic patients [5]. However, the lack of significant treatment effect of losmapimod on vascular inflammation in this inflamed COPD cohort, is in contrast to our atherosclerosis data. We previously reported a treatment effect of -0.10 (95% CI: 0.19, -0.02; p = 0.01) on TBR after 12 weeks of losmapimod treatment in atherosclerosis patients already established on stable statin therapy [5]. Important differences between the two trials include the disease population targeted, and duration of therapy (16 weeks in our current
Fig 5.  A) Plot of fibrinogen in the losmapimod and placebo treatment groups. Geometric mean of ratio to baseline value (95% CI) represented. “off drug” B) Plot of hsCRP in losmapimod and control groups. Geometric mean of ratio to baseline value (95% CI) represented. “off drug.”

https://doi.org/10.1371/journal.pone.0194197.g005
trial versus 12 weeks previously). However, given the significant *post hoc* results when COPD exacerbators were excluded, a possible explanation for lack of significant treatment effect is that the small treatment effect of losmapimod could have been masked by a much greater effect of exacerbations on vascular inflammation in COPD, particularly given this was a fibrinogen-enriched cohort, a group predisposed to frequent COPD exacerbations [13]. These data therefore suggest that exacerbations are likely to increase arterial inflammation, and provides a mechanistic explanation for the increased risk of cardiovascular events in COPD patients presenting with exacerbations [25]. We did not examine correlations between systemic inflammatory biomarkers and TBR in this COPD study, since only patients with higher levels of fibrinogen were included. However, given these COPD patients with systemic inflammation do have higher levels of arterial inflammation, than what we observed in stable atherosclerosis patients, supports the concept that arterial inflammation is a plausible mechanism accounting for increased cardiovascular risk observed in chronic inflammatory conditions [23].

There was no effect of losmapimod on the co-primary endpoint of endothelial function. However, significantly greater vasodilatation following GTN administration was observed in the losmapimod group. These data suggest that losmapimod may improve endothelium-independent vasodilatation in COPD, and interestingly this effect of losmapimod has been observed previously in hypercholesterolemic patients [6]. In the hypercholesterolemia study, however, losmapimod improved endothelium-dependent *and* endothelium-independent vasodilatation, but endothelial function was assessed by forearm venous occlusion plethysmography and intra-arterial acetylcholine infusion, and the study period was considerably shorter at 28 days.

Treatment with losmapimod did not alter arterial stiffness in this study. However, this may be expected since arterial stiffness may not be related to systemic inflammation in COPD patients, at least in cross-sectional analyses [26]. Mechanical changes to the arterial wall, particularly of the large central arteries, such as calcification [27], and, or reduced elastin in the arterial wall, potentially due to the detrimental systemic effects of smoking per-se may be a more robust explanation accounting for the increased arterial stiffness reported in COPD patients.

Pharmacological inhibition of the p38 MAPK pathway is associated with dampening of circulating systemic inflammatory biomarkers particularly in the short-term, and fibrinogen has most widely been assessed in COPD, and hsCRP in cardiovascular disease. The greatest reduction in these biomarkers is generally observed in the first 2–4 weeks following MAPK inhibition, with a gradual drift up from this nadir thereafter, and often a rebound of higher levels than baseline upon cessation of treatment [3] [5]. The pattern of attenuation in our fibrinogen data is similar, with a statistically significant reduction in fibrinogen at 2–4 weeks only. In contrast, two previous studies of losmapimod in COPD, demonstrated sustained lowering of fibrinogen with losmapimod treatment, at 12 weeks [4] [28]. The trajectory of fluctuations in hsCRP across the treatment period in our small trial, which are likely due to exacerbations, highlight the difficulty of interpreting inflammatory biomarker data in this current study.

Limitations of this exploratory study are the relatively small study size which may have restricted our ability to detect a smaller treatment effect than we predicted, based on data from a different population [5]. Further, the exacerbations which occurred in this cohort, which is consistent with the current understanding that fibrinogen predicts these events, makes discriminating small anti-inflammatory effects more difficult. Moreover, we chose a 4 month treatment period, whereas losmapimod reduced arterial inflammation in atherosclerosis patients at 3 months [5], and improved endothelial function in hypercholesterolemic subjects following 1 month of treatment [6]. These data suggest that the ideal treatment duration of losmapimod may be in the acute setting, or for shorter periods of therapy, similar to the use of corticosteroids in exacerbations.
To the best of our knowledge, this is the first trial to use fibrinogen as a stratification biomarker for entry to a COPD study. The clinical implications of fibrinogen reduction previously reported in losmapimod studies in COPD are currently unclear, but fibrinogen in COPD, is associated with poor outcomes and is a more stable biomarker than CRP [29], which supported its use as a stratification biomarker in this study. Indeed, the FDA has qualified fibrinogen as a drug development tool to be used in studies where patients are at high risk of exacerbations and mortality [13], and the stable levels of fibrinogen in the EVOLUTION placebo group over 4 months, and incidence of COPD exacerbations in the study, further support its utility as a drug development tool.

In summary, 16 weeks treatment with losmapimod was well tolerated but demonstrated no effect on index vessel inflammation and only a short-term reduction in systemic inflammation biomarkers in this cohort of COPD patients with evidence of systemic inflammation. Although endothelial-independent vasodilatation responses improved with losmapimod, there was no change in endothelial-dependent vasodilatation. These findings suggest that losmapimod is unlikely to be an effective long-term treatment for the adverse cardiovascular extra-pulmonary manifestations of COPD.

Supporting information
S1 Protocol. EVOLUTION trial protocol. (PDF)
S1 Appendix. CONSORT checklist EVOLUTION trial. (DOC)
S2 Appendix. Raw data. (ZIP)
S1 Methods. (DOCX)
S1 Table. Inclusion criteria of the trial. (DOCX)
S2 Table. Exclusion criteria of the trial. (DOCX)
S3 Table. Breakdown of trial screen failures. (DOCX)
S4 Table. Covariate data used to evaluate trial endpoints. (DOCX)
S5 Table. Summary of adverse events in the placebo and losmapimod groups. (DOCX)
S1 Fig. Flow-chart of trial visits and assessment. (TIFF)

Acknowledgments
We would like to thank the patients who took part in this study. We would also like to thank the staff at the NIHR Respiratory Biomedical Research Unit at the Royal Brompton & Harefield NHS Foundation Trust and Imperial College, and the Cambridge Clinical Trials Unit and
NIHR Comprehensive Biomedical Research Centre at Cambridge University Hospitals NHS Foundation Trust for their help with conducting this work. We also would like to thank the staff at the PET-CT unit at Cambridge University Hospitals NHS Foundation Trust and Inova Ltd, Hammersmith.

Author Contributions
Conceptualization: Joseph Cheriyan, Carmel M. McEniery, Jonathan Fuld, David A. Lomas, John R. Cockcroft, Ruth Tal-Singer, Michael I. Polkey, Ian B. Wilkinson.
Data curation: Marie Fisk, Divya Mohan, Nicholas S. Hopkinson.
Formal analysis: Marie Fisk, Julia Forman, James H. F. Rudd, Ian B. Wilkinson.
Funding acquisition: Joseph Cheriyan, Carmel M. McEniery, John R. Cockcroft, Michael I. Polkey, Ian B. Wilkinson.
Investigation: Joseph Cheriyan, Divya Mohan, Jonathan Fuld, John R. Cockcroft, Michael I. Polkey, Ian B. Wilkinson.
Methodology: Marie Fisk, Joseph Cheriyan, Kaisa M. Mäki-Petäjä, Michael I. Polkey, Ian B. Wilkinson.
Resources: Ruth Tal-Singer.
Supervision: Joseph Cheriyan, James H. F. Rudd, Ruth Tal-Singer, Ian B. Wilkinson.
Validation: Marie Fisk, Ian B. Wilkinson.
Writing – original draft: Marie Fisk.
Writing – review & editing: Joseph Cheriyan, Divya Mohan, Julia Forman, Kaisa M. Mäki-Petäjä, Carmel M. McEniery, Jonathan Fuld, James H. F. Rudd, Nicholas S. Hopkinson, David A. Lomas, John R. Cockcroft, Ruth Tal-Singer, Ian B. Wilkinson.

References
1. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009 May; 33(5):1165–85. https://doi.org/10.1183/09031936.00128008 PMID: 19407051
2. Singh D. P38 inhibition in COPD: cautious optimism. Thorax. 2013 Jul 9; 68(8):705–6. https://doi.org/10.1136/thoraxjnl-2013-203498 PMID: 23611882
3. Fisk M, Gajendra gadkar PR, Maki-Petaja KM, Wilkinson IB, Cheriyan J. Therapeutic Potential of p38 MAP Kinase Inhibition in the Management of Cardiovascular Disease. Am J Cardiovasc Drugs. 2014 Feb 7; 14(3):155–65. https://doi.org/10.1007/s40256-014-0063-6 PMID: 24507469
4. Lomas DA, Lipson DA, Miller BE, Willits L, Keene O, Barnacle H, et al. An Oral Inhibitor of p38 MAP Kinase Reduces Plasma Fibrinogen in Patients With Chronic Obstructive Pulmonary Disease. The Journal of Clinical Pharmacology. 2013 Mar 7; 52(3):416–24.
5. Elkhawad M, Rudd JHF, Sarov-Blat L, Cai G, Wells R, Davies LC, et al. Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis. JACC: Cardiovascular Imaging. 2012 Sep; 5(9):911–22. https://doi.org/10.1016/j.jcmg.2012.02.016 PMID: 22974804
6. Cheriyan J, Webb AJ, Sarov-Blat L, Elkhawad M, Wallace SML, Maki-Petaja KM, et al. Inhibition of p38 Mitogen-Activated Protein Kinase Improves Nitric Oxide–Mediated Vasodilatation and Reduces Inflammation in Hypercholesterolemia. Circulation. 2011 Feb 8; 123(5):515–23. https://doi.org/10.1161/CIRCULATIONAHA.110.971986 PMID: 21262998
7. Newby LK, Marber MS, Melloni C, Sarov-Blat L, Aberle LH, Aylward PE, et al. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial. Lancet. 2014 Sep 27; 384(9949):1187–95. https://doi.org/10.1016/S0140-6736(14)60417-7 PMID: 24930726
8. Figueroa AL, Abdelbaky A, Truong QA, Corsini E, MacNabb MH, Lavender ZR, et al. Measurement of arterial activity on routine FDG PET/CT images improves prediction of risk of future CV events. JACC: Cardiovascular Imaging. 2013 Dec; 6(12):1250–9. https://doi.org/10.1016/j.jcmg.2013.08.006 PMID: 24269261

9. Anderson TJ. Prognostic significance of brachial flow-mediated vasodilation. Circulation. 2007 May 8; 115(18):2373–5. https://doi.org/10.1161/CIRCULATIONAHA.107.697045 PMID: 17485590

10. Fisk M, Cheriyen J, McEniery CM, Cockcroft JR, PhD JH FR, Fryer TD, et al. Chronic Obstructive Pulmonary Disease (COPD) and Alpha-1 Antitrypsin Deficiency (A1ATD) are Associated With Increased Aortic Inflammation and Stiffness. Vol. 132, Circulation. 2015 Nov.

11. Eickhoff P, Valipour A, Kiss D, Schredere M, Cekici L, Geyer K, et al. Determinants of Systemic Vascular Function in Patients with Stable Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2008 Dec 15; 178(12):1211–8. https://doi.org/10.1164/rccm.200709-1412OC PMID: 18836149

12. Tousoulis D, Papageorgiou N, Andreoukis E, Antoniades C, Stefanadis C. Fibrinogen and cardiovascular disease: genetics and biomarkers. Blood Rev. 2011 Nov; 25(6):239–45. https://doi.org/10.1016/j.bler.2011.05.001 PMID: 21652129

13. Miller BE, Tal-Singer R, Rennard SI, Furwautenger L, Leidy N, Lowings M, et al. Plasma Fibrinogen Qualification as a Drug Development Tool in Chronic Obstructive Pulmonary Disease. Perspective of the Chronic Obstructive Pulmonary Disease Biomarker Qualification Consortium. Am J Respir Crit Care Med. 2016 Mar 15; 193(6):607–13. https://doi.org/10.1164/rccm.201509-1722PP PMID: 26745765

14. Fisk M, Mohan D, Cheriyen J, Yang L, Fuld J, McEniery CM, et al. Evaluation of losmapimod in patients with chronic obstructive pulmonary disease (COPD) with systemic inflammation stratified using fibrinogen ("EVOlution") Artery Research. 2014; 8(1):24–34.

15. Wan ES, Hokanson JE, Murphy JR, Regan EA, Make BJ, Lynch DA, et al. Clinical and Radiographic Predictors of GOLD–Unclassified Smokers in the COPDGene Study. Am J Respir Crit Care Med. 2011 Jul; 184(1):57–63. https://doi.org/10.1164/rccm.201101-0021OC PMID: 21493737

16. Danesh J. Plasma Fibrinogen Level and the Risk of Major Cardiovascular Diseases and Nonvascular Mortality. JAMA. 2005; 294(14):1799–809. https://doi.org/10.1001/jama.294.14.1799 PMID: 16219884

17. Dahl M, Tybjaerg-Hansen A, Vestbo J, Lange P, Nordestgaard BG. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001 Sep 15; 164(6):1008–11. https://doi.org/10.1164/ajrccm.164.6.2010067 PMID: 11587987

18. Sin DD, Man SFP. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proceedings of the American Thoracic Society. 2005; 2(1):8–11. https://doi.org/10.1513/pats.200404-032MS PMID: 16113462

19. Rudd JHF, Myers KS, Bansilal S, Machac J, Rafique A, Farthou M, et al. 18Fluorodeoxyglucose Positron Emission Tomography Imaging of Atherosclerotic Plaque Inflammation Is Highly Reproducible. Journal of the American College of Cardiology. 2007 Aug; 50(9):892–6. https://doi.org/10.1016/j.jacc.2007.05.024 PMID: 17719477

20. Corretti MC, Anderson TJ. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Reactivity Task Force. Journal of the American College of Cardiology. 2002; 39(2):257–65. PMID: 11788217

21. Wilkinson IB, Fuchs SA, Jansen IM, Spratt JC, Murray GD, Cockcroft JR, et al. Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. J Hypertens. 1998 Dec; 16(12 Pt 2):2079–84. PMID: 9886900

22. Nieuwenhuizen W. Biochemistry and measurement of fibrinogen. European Heart Journal. 1995 Mar; 16 Suppl A:6–10–discussion10.

23. Maki-Petaja KM, Elkhawad M, Cheriyen J, Joshi FR, Ostor AJK, Hall FC, et al. Anti-Tumor Necrosis Factor- Therapy Reduces Aortic Inflammation and Stiffness in Patients With Rheumatoid Arthritis. Circulation. 2012 Nov 20; 126(21):2473–80. https://doi.org/10.1161/CIRCULATIONAHA.112.120410 PMID: 23095282

24. Tawakol A, Fayad ZA, Mogg R, Alon A, Klimas MT, Dansky H, et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter Fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. Journal of the American College of Cardiology. 2013 Sep 3; 62(10):909–17. https://doi.org/10.1016/j.jacc.2013.04.066 PMID: 23727083

25. Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased risk of myocardial infarction and stroke following exacerbation of COPD. CHEST. 2010 May; 137(5):1091–7. https://doi.org/10.1378/che st.09-2029 PMID: 20022970

26. Mohan D, Polkey MI, Forman JR. Fibrinogen Is Not Associated With Cardiovascular And Muscular Co-morbidities In Chronic Obstructive Pulmonary Disease: The ERICA Study. Am J Respir Crit Care Med. Meeting Abstracts. 2016; 193:A3553.
27. Bolton CE, McEniery CM, Raj V, McDonnell BJ, Dixon AK, Munnery M, et al. Aortic calcification, arterial stiffness and bone mineral density in patients with COPD. Artery Research. 2011 Mar 1; 5(1):30–6.

28. Watz H, Barnacle H, Hartley BF, Chan R. Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014 Jan; 2(1):63–72. https://doi.org/10.1016/S2213-2600(13)70200-5 PMID: 24461903

29. Duvoix A, Dickens J, Haq I, Mannino D, Miller B, Tal-Singer R, et al. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax. 2013 Jun 15; 68(7):670–6. https://doi.org/10.1136/thoraxjnl-2012-201871 PMID: 22744884